Product logins

Find logins to all Clarivate products below.


Male Hypogonadism – Current Treatment – Treatment Algorithms: Claims Data Analysis – Male Hypogonadism (Low Testosterone) (US)

Male hypogonadism (low testosterone [low T]) is a condition characterized by impaired spermatogenesis and low serum testosterone. The majority of cases are caused by low T driven by age or comorbidities (e.g., obesity). Testosterone replacement therapy (TRT), which aims to increase overall serum testosterone levels, is the cornerstone of treatment and is primarily administered via injection, oral, or topical means. The availability of oral testosterone undecanoate medications like Jatenzo and Tlando has helped reduce the risk of adverse reactions at the injection site that are typical of intramuscular testosterone injections. However, a key drawback of TRT is reduced spermatogenesis, and some alternative therapies for low T focus on stimulating gonadotropins to preserve fertility. Additionally, the FDA has cautioned against the use of TRT because of the possibility of increased cardiac risk. We evaluate U.S. physician prescribing and treatment strategies in this arena based on patient-level claims data.

Questions answered

  • What shares do key therapies and brands garner by line of therapy in newly diagnosed low T patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed low T patients?
  • How have testosterone cypionate injection, testosterone enanthate injection, testosterone gel, Jatenzo, and others been integrated into the treatment algorithm, and what are their sources of business?
  • What percentage of low T patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of low T patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

Geography: United States

Key drugs covered: Jatenzo, testosterone cypionate, Tlando, Xyosted

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Key feature

Dashboard featuring interactive visuals, easy navigation, and expanded analyses

Related Market Assessment Reports

Report
Postpartum Depression – Current Treatment – Treatment Algorithms: Claims Data Analysis – Postpartum Depression (US)
Postpartum depression (PPD) refers to depression experienced by women after childbirth. The PPD drug market consists of very limited treatment options specifically approved for PPD, so drugs used…
Report
Type 1 Diabetes – Current Treatment – Treatment Algorithms: Claims Data Analysis – Type 1 Diabetes (US)
Intensive insulin regimens have proven effective in delaying the progression of complications associated with untreated or poorly treated type 1 diabetes (T1D). Thus, insulin remains the…
Report
Biosimilars – Current Treatment – Ophthalmology
The ophthalmology market is relatively new in the field of biosimilars: Samsung Bioepis / Biogen’s ranibizumab biosimilar, Byooviz, was the first MAb biosimilar to launch in the U.S. market in…
Report
Venous Thromboembolism – Current Treatment – Treatment Algorithms: Claims Data Analysis – Venous Thromboembolism (US)
Venous thromboembolism (VTE) is the obstruction of a vein caused by a thrombus. It consists of deep vein thrombosis (DVT) and pulmonary embolism (PE), depending on the vein affected. Current…
Report
Thyroid Eye Disease – Executive Insights – Thyroid Eye Disease | Executive Insights (US)